Delcath Systems Inc (DCTH) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows promising revenue growth and expansion plans, the recent price decline, lack of significant trading signals, and negative earnings trends suggest waiting for a more stable entry point.

Technical Analysis

The MACD histogram is slightly positive at 0.0137 but contracting, RSI is neutral at 32.962, and moving averages are converging, indicating no clear trend. The stock is trading near its S1 support level at 9.026, with resistance at 10.063. Overall, the technical indicators suggest a neutral trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have raised the price target to $29, indicating long-term growth potential.

Neutral/Negative Catalysts

The stock experienced a significant price drop of -11.85% during the regular market session and -6.95% in pre-market trading. The Q4 financials show a decline in net income (-44.20% YoY) and EPS (-54.55% YoY), which may concern investors.

Financial Performance

In Q4 2025, revenue increased by 37.27% YoY to $20.73 million, but net income dropped to -$1.896 million (-44.20% YoY), and EPS fell to -$0.05 (-54.55% YoY). Gross margin slightly declined to 85.48% (-0.51% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Clear Street raised the price target to $29 from $28 and maintained a Buy rating, citing predictable quarter-to-quarter variability and growth potential driven by Hepzato.

5 Analyst Rating

Wall Street analysts forecast DCTH stock price to rise

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.900

Low

Averages

24.5

High

Current: 8.900

Low

Averages

24.5

High

Clear Street

Buy

downgrade

$29 -> $27

AI Analysis

2026-02-26

New

Reason

Clear Street

Price Target

$29 -> $27

AI Analysis

2026-02-26

New

downgrade

Buy

Reason

Clear Street lowered the firm's price target on Delcath Systems to $27 from $29 and keeps a Buy rating on the shares. The firm notes Delcath reported FY25 earnings, which were in line with the preliminary results announced earlier this year. Guidance was issued for at least $100M in sales for FY26, against consensus estimate of $111M, and R&D and SG&A are expected to increase by nearly 90% and nearly 50% to support label expansion and HEPZATO commercial footprint expansion, respectively, in 2026. Clear Street sees weakness in the stock today as "myopia on the 2026 guidance," and notes that the increase in expenses should drive both growth in HEPZATO in the near term and label expansion in the long term, the two key drivers of its thesis.

Clear Street

Buy

maintain

$28 -> $29

2026-01-09

Reason

Clear Street

Price Target

$28 -> $29

2026-01-09

maintain

Buy

Reason

Clear Street raised the firm's price target on Delcath Systems to $29 from $28 and keeps a Buy rating on the shares after the company announced preliminary Q4 results. Hepzato is now a "steady contributor for Delcath, with quarter-to-quarter variability more predictable, growth still available, and cash flow to fund expansion indications, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DCTH

Unlock Now

DCTH Should I Buy

DCTH Should I Buy

Should You Buy Delcath Systems Inc (DCTH) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch